Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

3-Meomc

This article is a stubmissing:
Subjective Effects
Interactions
Tolerance
Legality
3-Meomc molecule structure3-Meomc molecule structure
Open in Piru

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~25 mg
Light25-50 mg
Moderate50-100 mg
Strong100-150 mg
Heavy150+ mg

Duration

Total5-7 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacodynamics

3-MeOMC promotes the release of dopamine, serotonin, and norepinephrine. One in vitro study suggests preferential dopamine and serotonin release, with weaker norepinephrine release at the tested concentration. Another publication reports potent norepinephrine release, supporting activity as a serotonin–norepinephrine–dopamine releasing agent without the same apparent selectivity.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

3-MeOMC has habit-forming potential.

History & Culture

3-MeOMC first appeared as an illicit drug after 2014 and had a short history of human use.

Legality

Legality not written up yet

References

Citations

  1. The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes. Psychopharmacology (2019). https://doi.org/10.1007/s00213-018-5063-9123
  2. Systematic Structure–Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents. ACS Chemical Neuroscience (2019). https://doi.org/10.1021/acschemneuro.8b005241

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 3-Meomc article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.